Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The hepatic gluconeogenesis enzyme system refers to the collection of enzymes and regulatory proteins in the liver that catalyze and control gluconeogenesis—the metabolic pathway responsible for synthesizing glucose from non-carbohydrate precursors such as lactate, amino acids, and glycerol. This process is essential for maintaining blood glucose levels during fasting or prolonged exercise. Targeting components or regulators of this system is a therapeutic strategy for managing type 2 diabetes.
Drugs targeting this system aim to reduce hepatic glucose production by inhibiting key gluconeogenic enzymes or modulating regulatory proteins.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Hepatic Gluconeogenesis Enzyme System.